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Serum and urinary high density lipoproteins in glomerular
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Serum and urinary high density lipoproteins in glomerular disease with
proteinuria. The serum lipoprotein concentrations, including
high—density lipoprotein (HDL) subfractions and apolipoproteins Al
and B were measured in 21 patients (14 male and seven female) with
nephrotic range proteinuria (>3g124hr), well maintained renal function
(creatinine clearance >35 mliter/min/l .73m2) and biopsy—proven pri-
mary glomerular disease. In these, and in a further five patients
(creatinine clearance >15 mliter/min/I.73m2), urinary apolipoprotein
Al output was determined. Total HDL cholesterol was similar in
patients and controls, but in male patients, HDL2 was low (0.54 0.10
mmole/liter, mean sEM) compared to controls (0.75 0.04
mmole/liter, P < 0.05) and l-IDL3 was high (0.81 0.07 in patients and
0.63 0.02 mmole/liter in controls, P < 0.01). In women, there was a
similar tendency for HDL2 to be lower in patients (0.68 0.18
mmole/liter) than in controls (0.85 0.10 mmole/liter). Multiple regres-
sion analysis revealed that major determinants of the urinary apolipo-
protein Al output were the urinary protein output and selectivity index
(multiple r = 0.85). Furthermore, some patients lost apolipoprotein Al
into their urine at rates indicating increased production of apolipopro-
tein Al in the nephrotic syndrome. The serum HDL subfraction
concentrations in the nephrotic syndrome could be exaplained by a
combination of increased HDL production and increased urinary loss of
low molecular wt HDL.
The association between lipemic serum and coaguable urine
hasbeen recognized for over 150 years [1], and by the early part
of this century the occurrence of hypercholesterolemia [21 and
hypertriglyceridemia [31 in the nephrotic syndrome (NS) was
established. Later, serum lipoproteins were studied in ne-
phrotic patients [4—9]. Changes in serum lipoprotein concentra-
tions are relevant to the controversial issue of whether or not
the risk of ischemic heart disease (IHD) in NS is increased
[9—12]. With the renewed interest in low levels of serum high
density lipoprotein (HDL) as a risk factor for IHD [13, 14],
recent reports have paid particular attention to HDL concen-
trations [7—9]. The HDL2 subfraction of HDL as opposed to the
HDL3 subfraction accounts for much of the variation in serum
HDL concentration in the general population, and it is the
HDL2 subfraction which is probably most closely associated
with IHD risk [15, 161. Thus far, however, there are no reports
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of serum HDL subfractions in patients with NS but without
severe renal failure. Altered lipoprotein metabolism in NS may
be due to a variety of factors [17] including the loss of HDL in
the urine [181. We have studied serum lipid and lipoprotein
concentrations, including HDL subfractions, and, as a marker
of urinary HDL output, urinary apolipoprotein Al (apo Al)
concentration, in a well characterized group of patients with NS
and relatively well preserved creatinine clearance.
Methods
Patients
Forty-one adult patients (over 16 years of age) with
biopsy—proven glomerular disease currently attending the out-
patient clinic were studied. Blood was taken after a 12 hr fast
and urine collected for 24 hr. Age, sex, height, wt and blood
pressure were recorded, and all patients were interviewed
regarding their cigarette and alcohol consumption, exercise
pattern and current drug therapy. Of these 41 patients, 21 had
both proteinuria >3g124hr and a creatinine clearance >
35m1/min/l.73m2. None of these 21 had evidence ofmultisystem
disease such as diabetes mellitus or systemic lupus
erythematosus, and none had received corticosteroid or
cytotoxic therapy within the previous three months. The histo-
pathological diagnoses were: membranous nephropathy in
eight, mesangiocapillary glomerulonephritis in four, mesangial
proliferative glomerulonephritis in three, focal and segmental
glomerulosclerosis in three and one each of crescentic glomer-
ulonephritis, familial nephritis and 'steroid—resistant—no—light—
microscopic—change NS". Six patients (four male and two
female) were taking beta blocking drugs and ten patients were
prescribed diuretics (furosemide in eight and athiazide in two).
The control groups consisted of 82 males from a local factory
and 19 female nurses and laboratory staff. They were all
apparently healthy, none had any historical evidence of IHD or
were taking drugs known to affect lipoprotein metabolism. A
further five of the original 41 patients (three with membranous
nephropathy, one focal and segmental glomerulosclerosis and
one steroid—resistant—no—light—microscopic—change NS) who
conformed to all the above criteria, except that their creatinine
clearances were between 15 and 35 mliter/min/l.73m2, were
included in the analysis of the factors determining urinary apo
Al excretion after it had been established that creatinine
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Table 1. Characteristics (mean SEM) of the 21 patients and 101 controls studied in the analysis of serum lipid and lipoprotein concentrations
Male
patients
Male
controls
Female
patients
Female
controls
Number
Age
Quetelet index
Cigarette smokers
Alcohol intake**
Duration of proteinuria**
Plasma albumin
Creatinine clearance
Urine protein***
years
%
g/week
months
g/liter
mliter per mm per 1.73 m2
g/24 hr
14
44 4
27 0.8
29
31.5;0—524
43;12—120
31.8 1.5
74 9
9.7;3,2—29
82
50 1
25.8 0.4
29
99;0—810
—
—
—
—
7
34 5
27.7 1.9*
29
0;0—136
97;9—l71
31.9 1.7
75 15
6.4;3.6—17
19
41 4
23.6 0.7
37
l7;0—117
—
—
—
—
Symbols are: * P = 0.02; * * median;range; '"" geometric mean;range.
clearances of this level had no independent effect on urinary
apo Al output. One patient was excluded from the multiple
regression analysis because of insufficient data.
Laboratory methods
Serum lipoproteins were isolated by ultracentrifugation at
100,000 x g (Superspeed 65 and 18 x 6.5m1, Aluminium Rotor,
MSE Limited, Crawley, Sussex, U.K.) and tube—slicing
(Spinco Tube Slicer, Beckman Instruments, Inc., Palo Alto,
California, USA). VLDL was separated as the supernatant after
ultracentrifugation of plasma for 24 hr and HDL and HDL3 as
infranatants after adjustment of plasma density to 1.063 g'mliter
and 1.125 glmliter respectively, and ultracentrifugation after 48
hours [19, 20]. Cholesterol and triglycerides in serum and
lipoproteins were determined enzymatically, (cholesterol re-
agents from DiaLab Ltd., Macclesfield, Cheshire, U.K. and
triglycerides by Peridochrome method, Boehringer Mannheim
Corporation Ltd., Lewes, E. Sussex, U.K.). The concentration
of HDL2 cholesterol was calculated by subtraction of HDL3
cholesterol concentration from that of total HDL. Serum LDL
cholesterol concentration was calculated from serum
triglycerides and HDL cholesterol [211. Serum apolipoprotein B
(apo B) and serum and urinary apo Al were determined by
electroimmunoassay [22, 23]. Plasma albumin and creatinine
were measured using standard autoanalyzer methods in the
service laboratory. Urine protein was measured by a turbido-
metric method and selectivity index was determined by the
ratio of IgG : transferrin clearances [24]. Before determination of
both apo Al and selectivity, urine was first concentrated tenfold
by dialysis against polyethylene glycol 6000 across a membrane
with a mean pore radius of 24 angstroms (Dialysis Tubing
Visking, Medicell International Ltd., London, U.K.). Pre- and
post-concentration assays had determined an apo Al recovery
of 84 0.98% (mean SEM, N = 10 experiments). Pre- and
post-results given in this report are uncorrected for recovery.
Statistical methods
Unpaired t-tests (two—tailed) were used to compare two
means with the appropriate corrections if the variances were
unequal. Log transformations were used for positively skewed
variables. Multiple linear regression analyses were carried out
according to the Statistical Package for the Social Sciences [25].
Table 2. Serum lipid and lipoprotein concentrations (mean sEas) III
14 male patients and 82 healthy mena
Male patients Male controls
Total serum cholesterol, mmole/liter 7.46 0.66 6.40 0.13
Total serum HDL cholesterol,
mmole/liter 1.35 0.09 1.40 0.04
Serum HDL2 cholesterol,
mmole/Iiter 0.54 0.lOc 0.75 0.04
Serum HDL3 cholesterol,
mmole/liter 0.81 0.07" 0.63 0.02
Serum LDL cholesterol, mmole/liter 5.09 0.58 4.33 0.14
Serum VLDL cholesterol,"
mmole/liter 0.94;0.32—2. 17* 0.45;0.07—4.23
Serum triglycerides," mmole/liter 1 .78;0.43—4.37 1.31 ;0.36—3.96
Serum apolipoprotein B, gluier 1.30 0.10 1.14 0.03
Serum apolipoprotein Al, gluier 0.88 0.05* 1.08 0.02
a Conversion factors; cholesterol: mgldliter = mmolelliter
triglycerides: mg/dliter = mmole/liter x 89.bgeometric mean;range; P < 0.05; "P < 0.01; P < 0.001.
Results
Characteristics of patients studied
x 39.
Age, alcohol and cigarette consumption were not significantly
different between patients and controls (Table 1). The female
patients were more obese than controls. In the patients, pro-
teinuria was never less than 3.2 gI24hr and had been present for
a minimum of nine months. Plasma albumin in men and women
was inversely related to the log urinary protein output (r =
—0.72, P < 0.001, N = 21).
Serum lipid and lipoprotein concentrations
In male patients serum HDL3 cholesterol concentration was
higher and HDL2 lower than in controls (Table 2). Like serum
HDL2, the concentration of serum apo Al was significantly
decreased in men with proteinuria. Concentrations of total
HDL cholesterol were, however, similar in the two groups of
men. Serum VLDL cholesterol was significantly higher in the
male patients, whereas serum triglycerides, serum cholesterol,
serum LDL cholesterol and serum apo B, although numerically
higher in the male patients, were not significantly different from
controls. In women, serum LDL cholesterol concentration was
increased in patients (Table 3). Otherwise, no statistically
significant differences were found. However, there were fewer
women than men, and with the exception of HDL3 cholesterol,
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Female
patients
Female
controls
Total serum cholesterol, mmole/liter 7.22 0.86 5.55 0.22
Total serum HDL cholesterol,
mmolelliter 1.55 0.24 1.77 0.14
Serum HDL2 cholesterol,
mmolelliier 0.68 0.18 0.85 0.10
Serum HDL3 cholesterol,
mmole/liter 0.87 0.20 0.92 0.07
Serum LDL cholesterol, mmolelliter 4.97 0.7V' 3.15 0.21
Serum VLDL cholesterol,"
mmolelliter 0.50;0.13—2.25 —
Serum triglycerides,' mmole/Iiter 1.42 ;0.80—2.40 1.27 ;0.78—6.03
Serum apolipoprotein B, g/Iiter 1.31 0.21 —
Serum apolipoprotein Al, glliter 0.96 0.10 —
the concentrations of which were similar in patients and con-
trols, trends were the same as those in men.
Analysis of flictors determining serum HDL suhfraction
cholesterol concentrations
Our male controls and patients were well matched with
respect to variables known to influence serum HDL. However,
in order to be sure that the differences in HDL subfractions
observed were not due to these other variables, multiple
regression analysis was undertaken. In our model, cigarette
smoking, alcohol consumption and nephrotic syndrome were
included as dummy variables and Quetelet Index (reciprocal),
log serum triglycerides and serum LDL cholesterol concentra-
tion as continuous variables. In the 96 men (14 patients and 82
controls) included in the analysis, nephrotic syndrome was the
only factor contributing significantly to the variation in HDL3
(P 0.001); for the full model multiple r 0.40, P 0.0 15.
There were, however, significant contributions to the variation
in serum HDL2 concentration from serum LDL cholesterol
concentration (P = 0.017) and to the variation in total HDL
cholesterol concentration from alcohol intake (P = 0.012) and
serum LDL cholesterol concentration (P = 0.015).
Determinants of urinary apolipoprotein Al
Determinants of urinary apo Al excretion were studied in 26
patients (creatinine clearances >15m1/min/1.73m2), details of
whom are shown in Table 4. There was no measurable urinary
apo Al (lower limit of detection 0.01 g/liter of concentrated
urine) in seven patients. Of these, the selectivity index was less
than 0.26 in six, whereas in 17 of 19 patients with detectable
urinary apo Al, the index was 0.26 or greater (P < 0.002,
two—tailed Fisher's exact test). In those in whom urinary apo
Al was detectable, its output was related to both selectivity
index (Fig. 1) (r = 0.66, P < 0.005) and to total urinary protein
output (r = 0.5, P < 0.005). A stepwise multiple linear
regression analysis was undertaken which included sex, serum
HDL, HDL2 and HDL3 cholesterol, log urinary protein output,
log selectivity index and creatinine clearance as variables in the
Male patients Female patients
Number 17 9
Urinary protein,' g124 hr 9.7;3.2—29.0 7.6;3.6—28.5
Total serum HDL cholesterol,
mmole/Iiter 1.32 0.08 1.52 0.21"
Serum HDL2 cholesterol,
mmole/!iier 0.51 0.09 0.63 0.17c
Serum HDL3 cholesterol,
mmole/Iiter 0.81 0.06 0.95 0.18
Selectivity indexb 0.33 ;0.16—0.80 0.30;0.l4—0.50
Urinary apolipoprotein Al,"
mg124 hr 9.3;0—450.4 32.2;0-.193
18 patients with detectable urinary apo Al in whom data was
complete. Only two of these variables made a significant (P <
0.05) contribution to the variation of urinary apo Al. These
were in order of importance log selectivity index (42% of
variation) and log urinary protein (27% of variation). The full
multiple regression equation was:
Table 3. Serum lipid and lipoprotein concentrations (mean 5EM) in
seven female patients and 19 healthy women
Table 4. Characteristics (mean sEM) of the 26 men and women
with proteinuria studied in the analysis of urinary apolipoprotein Al
excretion
"geometric mean ;range.
"P < 0.05.
For conversion factors, see Table 2.
• •
• •.
a median;range.
"geometric mean ;range.
N = 8.
1.0
0.9
0.8
0.7
0.6
0.5
x
0.4
>
>
U
a) 0.3
U)
0.2
0.1
1.0 10 100 1000
Urinary apo Al, mg/24hr
Fig. 1. Urinary apolipoprotein Al output as a function of selectivity
index in 19 patients with detectable urinary apo Al (•). r = 0.66, P <
0.001. Mean (± SEM) selectivity index of seven patients without
detectable urinary apo Al (0).
• •
•
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Urinary apo Al = 3.325 0.690 log selectivity index
+ 1.48 1 0.407 log urinary protein output
+ 1.440 0.513 (multiple r 0.83, P <
0.001).
Discussion
Patients with NS frequently have raised serum total LDL
cholesterol concentrations (6) but reports concerning serum
HDL cholesterol are conflicting; both high and low levels have
been found (6—9, 26, 27). This is probably because of consider-
able differences in other aspects of renal function, treatments
and other characteristics known to affect HDL metabolism.
This is the first report of HDL subfraction cholesterol levels
in patients with primary, biopsy—proven glomerular disease
with nephrotic range proteinuria (>3g124hr) and well main-
tained renal function (creatinine clearance >3SmlImin/l .73m2).
The patients had well maintained plasma albumin concentra-
tions despite heavy proteinuria. Our experience over many
years suggests that with the appropriate protein and calorie
supplementation, this can be achieved in most patients who are
metabolically stable. Our study demonstrates that raised serum
HDL3 and reduced HDL2 cholesterol are found in male pa-
tients despite normal total serum HDL cholesterol concentra-
tions. Furthermore, the rise in HDL3 in the proteinuria patients
was shown to be largely due to NS rather than to differences
between patients and controls in other variables known to
influence serum HDL subfractions. A similar trend towards
lower serum HDL2 cholesterol concentrations was observed in
women. However, we were able to study only a small number
of women with NS who were markedly obese. One earlier
report, however, describes lowered serum HDL2 cholesterol
concentrations, and occasionally raised serum HDL3 choles-
terol concentration, but this was in a group consisting mainly of
children who had severe renal impairment and relatively mod-
est proteinuria [7].
Lipiduria has long been recognized in NS [28] and it is well
established that much of this lipid is in lipoproteins of similar
hydrated density to HDL [18, 27, 29, 30]. In our study apo Al,
the major component of the protein moiety of HDL, was
determined in urine as a measure of the urinary HDL leak. Its
output was largely determined by the selectivity of the protein-
uria and by the total urinary protein. This conclusion is sup-
ported by an earlier report that selectivity was related to the
ratio of total urinary apo A to total proteinuria in younger
patients with non-minimal change NS [27]. The implication of
these findings is that the functional diameter of the abnormal
'leaky pores' in the glomerular basement membrane, and their
relative abundance as judged by the degree of proteinuria,
determine the quantity of HDL lost into the urine.
It might be anticipated that smaller HDL particles would be
lost into the urine in preference to larger ones, and therefore
that HDL3 (molecular wt 175,000 daltons and mean diameter of
55 angstroms) might be lost in preference to HDL2 (molecular
wt 360,000 daltons and mean diameter 85 angstroms), and
nascent HDL would be lost in preference to either of them. In
the serum however, HDL3 levels were high and HDL2 levels
were low. This apparent paradox may be explicable as follows:
in NS there is a general increase in hepatic lipoprotein secretion
[3 1—33] which is probably a consequence of low serum albumin
or lowered plasma oncotic pressure [6, 33]. In our patients,
indirect evidence for an increased production of HDL comes
from the observation that some of our male patients were losing
50 to 100% of the apo Al normally synthesized in a day [14, 34]
directly into their urine. Since their total serum HDL choles-
terol concentrations were normal, this indicates that those with
the greatest losses must have been able to at least double their
rate of apo Al production. This increase in rate of production of
apo Al presumably reflects increased production of nascent
HDL. The loss of HDL particles into urine will reduce their
plasma half life [34, 35] so that although nascent HDL may
remain in the circulation long enough to acquire sufficient
cholesterol to be converted to HDL3, substantial amounts of
both nascent HDL and HDL3 will have disappeared into the
urine before the larger HDL2 particles can be formed [7]. Such
an effect may be compounded by defects in the metabolism of
triglyceride rich lipoproteins [26, 31] which is also important for
the conversion of HDL3 to HDL2. The result would be an
increased HDL3 and a lowered HDL2 as found in this study.
The present findings should be considered in the context of
the controversy about the prevalence of IHD in NS [9—12]. High
levels of serum LDL and VLDL, both of which occur in NS,
are positive risk factors for the development of IHD in the
general population [36, 37], but serum HDL appears to be a
negative risk factor [13]. The levels of the HDL2 subfraction,
which were low in our patients with proteinuria, may be more
closely associated with this apparent protection [15, 161 than
those of HDL3, the other major subfraction of HDL. The
protein moiety of HDL2 is relatively richer in apo Al than that
of HDL3 [14] and this may account for the decreased serum
concentration of apo Al in our patients with proteinuria.
Decreased levels of serum apo Al have recently been shown to
be closely associated with coronary atheroma [38]. A tendency
for high levels of serum apo B similar to that in the proteinuria
patients in our study has also been implicated as an important
determinant of coronary atherosclerosis risk [39, 40]. Our
findings suggest that lipoprotein risk factors for IHD may vary
widely in patients with NS, and that such patients cannot be
considered as a homogenous group in this respect, a case we
have previously argued [11]. Patients with highly selective
proteinura (such as, minimal change nephropathy) or, more
specifically, a selectivity index of less than 0.26 and/or rela-
tively small degrees of proteinuria may lose very little HDL into
their urine. However, patients with heavy, poorly selective
proteinuria will lose a substantial amount of HDL into their
urine. This will account for a large proportion of the daily
turnover of HDL and be responsible, at least in part, for
abnormal levels of HDL subfractions, as reported here, and
lead to accelerated atherogenesis.
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